www.baxdela.com

This site is intended for US Healthcare Professionals. If you are a US Healthcare Professional, click OK to continue.

OK
CANCEL

Baxdela is your Path Forward.

Multiple factors impact the treatment of acute bacterial skin and skin structure infections (ABSSSI). BAXDELA is your path forward.

aBAXDELA clinical trials included a distribution of patients with obesity, hypertension, diabetes, and renal impairment (eGFR > 15 mL/min/1.73 m2).

Pathway to Efficacy

Broad coverage: gram-positive pathogens, including MRSA, and gram-negative pathogens, including Pseudomonas aeruginosa. See full Indication

See Baxdela Efficacy Results

Explore Safety
& Tolerability

See Baxdela Safety Profile

Dosing & Administration

Oral monotherapy

See BAXDELA Dosing & Administration

Patient Access

Explore Baxdela Options

Next: Introduction

Melinta Therapeutics, Inc. - The Antibiotics Company

Medical Information
For medical inquiries or to report an adverse event, other safety-related information, or product complaints for a company product, please contact Medical Information. Phone: 1-844-MED-MLNT (1-844-633-6568)
medinfo@melinta.com
www.melintamedicalinformation.com

©2019 All rights reserved. PP-BAX-0399 v3.0 Terms of Use

BAXDELA® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.